Alving B M, Tankersley D L, Mason B L, Rossi F, Aronson D L, Finlayson J S
J Lab Clin Med. 1980 Aug;96(2):334-46.
The intramuscular or intravenous administration of ISG prepared from human plasma by ethanol fractionation can elicit such reactions as pain at the injection site, flushing, and even hypotension. Similar adverse reactions to plasma protein fraction, a volume expander also made by ethanol fractionation, have been associated with PKA (Hageman factor fragments) in the product. Twenty-five lots of commercial ISG were therefore analyzed for PKA and kallikrein, components of the contact activation system which could mediate such reactions through the generation of kinins in recipients. Kallikrein activity ranged from undetectable levels to > 60% of the total potential kallikrein activity in normal plasma. PKA, which was measured by its ability to catalyze the conversion of prekallikrein to kallikrein, ranged from 5% to 3950% of the activity in a reference plasma protein fraction that had caused hypotension. All but five lots increased vascular permeability in the guinea pig. The five lots which caused no increased were also the lowest in PKA and kallikrein activity. When ISG ws subjected to gel chromatography to separate the enzymic contaminants from immunoglobulin G, only the fractions containing PKA and/or kallikrein increased vascular permeability. Several lots of ISG shortened the nonactivated partial thromboplastin time of normal plasma fro 236 sec to 38 to 55 sec. During gel chromatography, coagulation activity was eluted in a position corresponding to a molecular weight of 150,000; it was inhibited by antibody to human factor XI. These data indicate that factor XIa is responsible for the coagulant activity observed and that PKA and/or kallikrein are potential mediators of vasoactive reactions to ISG.
通过乙醇分级分离法从人血浆中制备的免疫血清球蛋白(ISG)进行肌内或静脉注射时,可引发注射部位疼痛、潮红甚至低血压等反应。对同样通过乙醇分级分离法制成的血容量扩充剂血浆蛋白分离液也有类似的不良反应,且与产品中的血浆激肽释放酶原激活剂(PKA,哈格曼因子片段)有关。因此,对25批市售ISG进行了PKA和激肽释放酶分析,这两种物质是接触激活系统的成分,可通过在接受者体内生成激肽来介导此类反应。激肽释放酶活性范围从检测不到到高于正常血浆中总潜在激肽释放酶活性的60%。PKA通过其催化前激肽释放酶转化为激肽释放酶的能力来测定,其活性范围为导致低血压的参考血浆蛋白分离液活性的5%至3950%。除五批外,所有批次的ISG均增加了豚鼠的血管通透性。未导致血管通透性增加的五批ISG的PKA和激肽释放酶活性也是最低的。当ISG进行凝胶色谱以从免疫球蛋白G中分离酶污染物时,只有含有PKA和/或激肽释放酶的级分增加了血管通透性。几批ISG将正常血浆的非活化部分凝血活酶时间从236秒缩短至38至55秒。在凝胶色谱过程中,凝血活性在对应于分子量150,000的位置被洗脱;它可被抗人因子XI抗体抑制。这些数据表明因子XIa是观察到的凝血活性的原因,并且PKA和/或激肽释放酶是对ISG血管活性反应的潜在介质。